Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys
British Journal of Pharmacology2019Vol. 177(2), pp. 388–401
Citations Over TimeTop 22% of 2019 papers
Qiuji Ye, Shishir Chourey, Chintam Nagendra Reddy, Rui Wang, Chantal Cossette, Sylvie Gravel, Irina Slobodchikova, Dajana Vuckovic, Joshua Rokach, William S. Powell
Abstract
Because of its highly potent antagonist activity and its long lifetime in vivo, S-Y048 may be a useful anti-inflammatory agent for the treatment of eosinophilic diseases such as asthma, allergic rhinitis, and atopic dermatitis.
Related Papers
- → Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite(2011)39 cited
- → Pharmacologically Active Drug Metabolites(1976)91 cited
- → Disposition of Pentopril, a New Orally Active Angiotensin-Converting Enzyme Inhibitor, and Its Active Metabolite in Rats(1985)7 cited
- → Pharmacokinetic Relationships Between Cinromide and Its Metabolites in the Rhesus Monkey I: 3-Bromocinnamamide, an Active Metabolite(1983)4 cited
- [The inhibitory effect of LTB4 antagonist on eosinophil infiltration in cutaneous and gut late phase response in BALB/C mice sensitized with ovalubumin (OVA)].(1997)